Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

EXPO vs HCI vs ICFI vs UPC vs CACI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
EXPO
Exponent, Inc.

Consulting Services

IndustrialsNASDAQ • US
Market Cap$3.12B
5Y Perf.-37.0%
HCI
HCI Group, Inc.

Insurance - Property & Casualty

Financial ServicesNYSE • US
Market Cap$1.99B
5Y Perf.+98.2%
ICFI
ICF International, Inc.

Consulting Services

IndustrialsNASDAQ • US
Market Cap$1.35B
5Y Perf.-20.4%
UPC
Universe Pharmaceuticals Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CN
Market Cap$2M
5Y Perf.-100.0%
CACI
CACI International Inc

Information Technology Services

TechnologyNYSE • US
Market Cap$10.82B
5Y Perf.+95.0%

EXPO vs HCI vs ICFI vs UPC vs CACI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
EXPO logoEXPO
HCI logoHCI
ICFI logoICFI
UPC logoUPC
CACI logoCACI
IndustryConsulting ServicesInsurance - Property & CasualtyConsulting ServicesDrug Manufacturers - Specialty & GenericInformation Technology Services
Market Cap$3.12B$1.99B$1.35B$2M$10.82B
Revenue (TTM)$582M$927M$1.82B$41M$9.16B
Net Income (TTM)$106M$314M$85M$-12M$537M
Gross Margin40.1%66.5%27.2%30.3%14.9%
Operating Margin20.6%47.9%7.9%-26.7%9.3%
Forward P/E29.9x8.9x9.9x17.1x
Total Debt$83M$68M$571M$9M$3.34B
Cash & Equiv.$222M$1.21B$5M$34M$106M

EXPO vs HCI vs ICFI vs UPC vs CACILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

EXPO
HCI
ICFI
UPC
CACI
StockMar 21May 26Return
Exponent, Inc. (EXPO)10063.0-37.0%
HCI Group, Inc. (HCI)100198.2+98.2%
ICF International, … (ICFI)10079.6-20.4%
Universe Pharmaceut… (UPC)1000.0-100.0%
CACI International … (CACI)100195.0+95.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: EXPO vs HCI vs ICFI vs UPC vs CACI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HCI leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Exponent, Inc. is the stronger pick specifically for dividend income and shareholder returns and operational efficiency and capital deployment. CACI also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
EXPO
Exponent, Inc.
The Income Pick

EXPO is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.

  • Dividend streak 13 yrs, beta 0.89, yield 1.9%
  • Beta 0.89, yield 1.9%, current ratio 2.40x
  • 1.9% yield, 13-year raise streak, vs HCI's 1.0%, (2 stocks pay no dividend)
  • 13.7% ROA vs UPC's -18.6%, ROIC 36.3% vs -7.8%
Best for: income & stability and defensive
HCI
HCI Group, Inc.
The Insurance Pick

HCI carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 20.2%, EPS growth 179.8%, 3Y rev CAGR 22.3%
  • 436.8% 10Y total return vs CACI's 416.4%
  • Lower volatility, beta 0.39, Low D/E 6.1%, current ratio 1.24x
  • PEG 0.19 vs EXPO's 5.02
Best for: growth exposure and long-term compounding
ICFI
ICF International, Inc.
The Lower-Volatility Pick

ICFI lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: industrials exposure
UPC
Universe Pharmaceuticals Inc.
The Healthcare Pick

Among these 5 stocks, UPC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
CACI
CACI International Inc
The Defensive Choice

CACI ranks third and is worth considering specifically for stability and momentum.

  • Beta 0.30 vs UPC's 1.26
  • +3.3% vs UPC's -41.1%
Best for: stability and momentum
See the full category breakdown
CategoryWinnerWhy
GrowthHCI logoHCI20.2% revenue growth vs UPC's -22.4%
ValueHCI logoHCILower P/E (8.9x vs 17.1x), PEG 0.19 vs 1.41
Quality / MarginsHCI logoHCI33.9% margin vs UPC's -30.3%
Stability / SafetyCACI logoCACIBeta 0.30 vs UPC's 1.26
DividendsEXPO logoEXPO1.9% yield, 13-year raise streak, vs HCI's 1.0%, (2 stocks pay no dividend)
Momentum (1Y)CACI logoCACI+3.3% vs UPC's -41.1%
Efficiency (ROA)EXPO logoEXPO13.7% ROA vs UPC's -18.6%, ROIC 36.3% vs -7.8%

EXPO vs HCI vs ICFI vs UPC vs CACI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

EXPOExponent, Inc.
FY 2025
Engineering And Other Scientific
84.9%$494M
Environmental And Health
15.1%$88M
HCIHCI Group, Inc.
FY 2025
Real Estate Operations
100.0%$15M
ICFIICF International, Inc.
FY 2023
Health Education And Social Programs
100.0%$814M
UPCUniverse Pharmaceuticals Inc.

Segment breakdown not available.

CACICACI International Inc
FY 2025
Technology Service
55.4%$4.8B
Service, Other
44.6%$3.8B

EXPO vs HCI vs ICFI vs UPC vs CACI — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHCILAGGINGCACI

Income & Cash Flow (Last 12 Months)

HCI leads this category, winning 6 of 6 comparable metrics.

CACI is the larger business by revenue, generating $9.2B annually — 224.1x UPC's $41M. HCI is the more profitable business, keeping 33.9% of every revenue dollar as net income compared to UPC's -30.3%. On growth, HCI holds the edge at +11.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricEXPO logoEXPOExponent, Inc.HCI logoHCIHCI Group, Inc.ICFI logoICFIICF International…UPC logoUPCUniverse Pharmace…CACI logoCACICACI Internationa…
RevenueTrailing 12 months$582M$927M$1.8B$41M$9.2B
EBITDAEarnings before interest/tax$125M$454M$201M-$10M$1.1B
Net IncomeAfter-tax profit$106M$314M$85M-$12M$537M
Free Cash FlowCash after capex$122M$431M$151M-$15M$470M
Gross MarginGross profit ÷ Revenue+40.1%+66.5%+27.2%+30.3%+14.9%
Operating MarginEBIT ÷ Revenue+20.6%+47.9%+7.9%-26.7%+9.3%
Net MarginNet income ÷ Revenue+18.2%+33.9%+4.7%-30.3%+5.9%
FCF MarginFCF ÷ Revenue+21.0%+46.4%+8.3%-37.2%+5.1%
Rev. Growth (YoY)Latest quarter vs prior year+7.8%+11.9%-10.3%-14.1%+8.5%
EPS Growth (YoY)Latest quarter vs prior year+6.5%+23.4%-22.2%-100.1%+17.8%
HCI leads this category, winning 6 of 6 comparable metrics.

Valuation Metrics

HCI leads this category, winning 4 of 7 comparable metrics.

At 6.1x trailing earnings, HCI trades at a 80% valuation discount to EXPO's 30.6x P/E. Adjusting for growth (PEG ratio), HCI offers better value at 0.13x vs EXPO's 5.15x — a lower PEG means you pay less per unit of expected earnings growth.

MetricEXPO logoEXPOExponent, Inc.HCI logoHCIHCI Group, Inc.ICFI logoICFIICF International…UPC logoUPCUniverse Pharmace…CACI logoCACICACI Internationa…
Market CapShares × price$3.1B$2.0B$1.3B$2M$10.8B
Enterprise ValueMkt cap + debt − cash$3.0B$844M$1.9B-$23M$14.1B
Trailing P/EPrice ÷ TTM EPS30.65x6.15x15.05x-0.00x21.95x
Forward P/EPrice ÷ next-FY EPS est.29.89x8.94x9.94x17.07x
PEG RatioP/E ÷ EPS growth rate5.15x0.13x1.31x1.81x
EV / EBITDAEnterprise value multiple22.99x1.92x9.13x14.65x
Price / SalesMarket cap ÷ Revenue5.37x2.20x0.72x0.09x1.25x
Price / BookPrice ÷ Book value/share8.33x1.77x1.33x0.00x2.82x
Price / FCFMarket cap ÷ FCF25.54x4.47x11.22x22.48x
HCI leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

HCI leads this category, winning 7 of 9 comparable metrics.

HCI delivers a 32.0% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-27 for UPC. HCI carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to CACI's 0.86x. On the Piotroski fundamental quality scale (0–9), HCI scores 8/9 vs UPC's 4/9, reflecting strong financial health.

MetricEXPO logoEXPOExponent, Inc.HCI logoHCIHCI Group, Inc.ICFI logoICFIICF International…UPC logoUPCUniverse Pharmace…CACI logoCACICACI Internationa…
ROE (TTM)Return on equity+25.5%+32.0%+8.3%-27.0%+13.1%
ROA (TTM)Return on assets+13.7%+13.2%+4.1%-18.6%+5.7%
ROICReturn on invested capital+36.3%+6.8%+7.2%-7.8%+9.2%
ROCEReturn on capital employed+19.2%+40.6%+9.3%-5.6%+11.6%
Piotroski ScoreFundamental quality 0–968647
Debt / EquityFinancial leverage0.21x0.06x0.56x0.16x0.86x
Net DebtTotal debt minus cash-$139M-$1.1B$566M-$24M$3.2B
Cash & Equiv.Liquid assets$222M$1.2B$5M$34M$106M
Total DebtShort + long-term debt$83M$68M$571M$9M$3.3B
Interest CoverageEBIT ÷ Interest expense67.24x6.75x-22.11x4.52x
HCI leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HCI leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in HCI five years ago would be worth $20,530 today (with dividends reinvested), compared to $3 for UPC. Over the past 12 months, CACI leads with a +3.3% total return vs UPC's -41.1%. The 3-year compound annual growth rate (CAGR) favors HCI at 45.7% vs UPC's -89.3% — a key indicator of consistent wealth creation.

MetricEXPO logoEXPOExponent, Inc.HCI logoHCIHCI Group, Inc.ICFI logoICFIICF International…UPC logoUPCUniverse Pharmace…CACI logoCACICACI Internationa…
YTD ReturnYear-to-date-9.1%-16.7%-12.5%-27.9%-8.8%
1-Year ReturnPast 12 months-13.6%+2.4%-11.0%-41.1%+3.3%
3-Year ReturnCumulative with dividends-24.4%+209.6%-32.1%-99.9%+61.2%
5-Year ReturnCumulative with dividends-28.5%+105.3%-16.9%-100.0%+85.4%
10-Year ReturnCumulative with dividends+186.1%+436.8%+100.5%-100.0%+416.4%
CAGR (3Y)Annualised 3-year return-8.9%+45.7%-12.1%-89.3%+17.3%
HCI leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — EXPO and CACI each lead in 1 of 2 comparable metrics.

CACI is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than UPC's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXPO currently trades 77.4% from its 52-week high vs UPC's 27.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricEXPO logoEXPOExponent, Inc.HCI logoHCIHCI Group, Inc.ICFI logoICFIICF International…UPC logoUPCUniverse Pharmace…CACI logoCACICACI Internationa…
Beta (5Y)Sensitivity to S&P 5000.86x0.38x0.56x1.11x0.29x
52-Week HighHighest price in past year$81.95$210.50$101.71$11.00$683.50
52-Week LowLowest price in past year$63.25$136.37$64.52$2.00$409.62
% of 52W HighCurrent price vs 52-week peak+77.4%+72.6%+73.2%+27.3%+71.7%
RSI (14)Momentum oscillator 0–10038.648.759.841.936.4
Avg Volume (50D)Average daily shares traded452K167K349K8K270K
Evenly matched — EXPO and CACI each lead in 1 of 2 comparable metrics.

Analyst Outlook

EXPO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: EXPO as "Buy", HCI as "Buy", ICFI as "Buy", CACI as "Buy". Consensus price targets imply 48.1% upside for CACI (target: $726) vs -17.2% for HCI (target: $127). For income investors, EXPO offers the higher dividend yield at 1.89% vs ICFI's 0.75%.

MetricEXPO logoEXPOExponent, Inc.HCI logoHCIHCI Group, Inc.ICFI logoICFIICF International…UPC logoUPCUniverse Pharmace…CACI logoCACICACI Internationa…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$85.00$126.50$102.50$725.50
# AnalystsCovering analysts8141329
Dividend YieldAnnual dividend ÷ price+1.9%+1.0%+0.8%
Dividend StreakConsecutive years of raises13282
Dividend / ShareAnnual DPS$1.20$1.50$0.56
Buyback YieldShare repurchases ÷ mkt cap+3.1%+0.1%+4.1%0.0%+1.6%
EXPO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

HCI leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). EXPO leads in 1 (Analyst Outlook). 1 tied.

Best OverallHCI Group, Inc. (HCI)Leads 4 of 6 categories
Loading custom metrics...

EXPO vs HCI vs ICFI vs UPC vs CACI: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is EXPO or HCI or ICFI or UPC or CACI a better buy right now?

For growth investors, HCI Group, Inc.

(HCI) is the stronger pick with 20. 2% revenue growth year-over-year, versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). HCI Group, Inc. (HCI) offers the better valuation at 6. 1x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Exponent, Inc. (EXPO) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — EXPO or HCI or ICFI or UPC or CACI?

On trailing P/E, HCI Group, Inc.

(HCI) is the cheapest at 6. 1x versus Exponent, Inc. at 30. 6x. On forward P/E, HCI Group, Inc. is actually cheaper at 8. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: HCI Group, Inc. wins at 0. 19x versus Exponent, Inc. 's 5. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — EXPO or HCI or ICFI or UPC or CACI?

Over the past 5 years, HCI Group, Inc.

(HCI) delivered a total return of +105. 3%, compared to -100. 0% for Universe Pharmaceuticals Inc. (UPC). Over 10 years, the gap is even starker: HCI returned +434. 8% versus UPC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — EXPO or HCI or ICFI or UPC or CACI?

By beta (market sensitivity over 5 years), CACI International Inc (CACI) is the lower-risk stock at 0.

29β versus Universe Pharmaceuticals Inc. 's 1. 11β — meaning UPC is approximately 288% more volatile than CACI relative to the S&P 500. On balance sheet safety, HCI Group, Inc. (HCI) carries a lower debt/equity ratio of 6% versus 86% for CACI International Inc — giving it more financial flexibility in a downturn.

05

Which is growing faster — EXPO or HCI or ICFI or UPC or CACI?

By revenue growth (latest reported year), HCI Group, Inc.

(HCI) is pulling ahead at 20. 2% versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). On earnings-per-share growth, the picture is similar: HCI Group, Inc. grew EPS 179. 8% year-over-year, compared to -14. 9% for ICF International, Inc.. Over a 3-year CAGR, HCI leads at 22. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — EXPO or HCI or ICFI or UPC or CACI?

HCI Group, Inc.

(HCI) is the more profitable company, earning 33. 2% net margin versus -20. 6% for Universe Pharmaceuticals Inc. — meaning it keeps 33. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCI leads at 47. 7% versus -16. 3% for UPC. At the gross margin level — before operating expenses — HCI leads at 73. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is EXPO or HCI or ICFI or UPC or CACI more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, HCI Group, Inc. (HCI) is the more undervalued stock at a PEG of 0. 19x versus Exponent, Inc. 's 5. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, HCI Group, Inc. (HCI) trades at 8. 9x forward P/E versus 29. 9x for Exponent, Inc. — 20. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CACI: 48. 1% to $725. 50.

08

Which pays a better dividend — EXPO or HCI or ICFI or UPC or CACI?

In this comparison, EXPO (1.

9% yield), HCI (1. 0% yield), ICFI (0. 8% yield) pay a dividend. UPC, CACI do not pay a meaningful dividend and should not be held primarily for income.

09

Is EXPO or HCI or ICFI or UPC or CACI better for a retirement portfolio?

For long-horizon retirement investors, HCI Group, Inc.

(HCI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 38), 1. 0% yield, +434. 8% 10Y return). Both have compounded well over 10 years (HCI: +434. 8%, UPC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between EXPO and HCI and ICFI and UPC and CACI?

These companies operate in different sectors (EXPO (Industrials) and HCI (Financial Services) and ICFI (Industrials) and UPC (Healthcare) and CACI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EXPO is a small-cap quality compounder stock; HCI is a small-cap high-growth stock; ICFI is a small-cap deep-value stock; UPC is a small-cap quality compounder stock; CACI is a mid-cap quality compounder stock. EXPO, HCI, ICFI pay a dividend while UPC, CACI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

EXPO

Income & Dividend Stock

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 10%
Run This Screen
Stocks Like

HCI

Quality Mega-Cap Compounder

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 20%
Run This Screen
Stocks Like

ICFI

Stable Dividend Mega-Cap

  • Sector: Industrials
  • Market Cap > $100B
  • Gross Margin > 16%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

UPC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 18%
Run This Screen
Stocks Like

CACI

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform EXPO and HCI and ICFI and UPC and CACI on the metrics below

Revenue Growth>
%
(EXPO: 7.8% · HCI: 11.9%)
Net Margin>
%
(EXPO: 18.2% · HCI: 33.9%)
P/E Ratio<
x
(EXPO: 30.6x · HCI: 6.1x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.